Form 4: Protara CEO Sells Shares for Tax Obligations
Insider Transaction Report
Protara Therapeutics CEO Jesse Shefferman disposed of 16,322 shares to cover tax obligations from RSU vesting.
Summary
- Jesse Shefferman, CEO and President of Protara Therapeutics, Inc., reported a transaction involving the company's common stock.
- On January 20, 2026, 16,322 shares of common stock were disposed of at a price of $5.6 per share.
- These shares were withheld by Protara Therapeutics to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards.
- The Restricted Stock Unit Awards were originally granted to Mr. Shefferman on January 19, 2023, and January 19, 2024.
- Following this transaction, Mr. Shefferman directly beneficially owns 1,030,564 shares of Protara Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common part of executive compensation. It does not indicate a change in management's view of the company's prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes related to executive compensation, not a discretionary sale by the insider.
Key Dates
| Date | Description |
|---|---|
| 01/19/2023 | Grant date of Restricted Stock Unit Awards. |
| 01/19/2024 | Grant date of Restricted Stock Unit Awards. |
| 01/20/2026 | Transaction date for the disposition of shares to satisfy income tax obligations. |
| 01/22/2026 | Signature date of the reporting person on the Form 4. |
Recommendation
holdThis Form 4 reports a routine, non-discretionary disposition of shares by the CEO to cover tax obligations arising from the vesting of Restricted Stock Units. Such transactions are common for executive compensation and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Protara Therapeutics, TARA, Jesse Shefferman, Form 4, Insider Transaction, Restricted Stock Units, RSU vesting, Tax obligations, Stock disposition, CEO stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.